NCT06864403

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: University of North Carolina, Chapel Hill · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if mirikizumab works to treat pouch disorders in adults. The main questions it aims to answer are: Does mirikizumab reduce symptoms of pouch disorders Participants will: Take mirikizumab every 4 weeks for one year Visit the clinic once every month for two months and at the end of the study Keep a diary of their symptoms

Conditions

• Pouchitis
• Pouches, Ileoanal
• Pouch, Ileal

Interventions

Type	Name	Description
DRUG	Mirikizumab - Intravenous (IV)	300 mg mirikizumab at Weeks 0, 4, and 8
DRUG	Mirikizumab - Subcutaneous (SC)	Pre-filled syringes administered at Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52.

Timeline

• Start date: 2025-08-12
• Primary completion: 2027-04-01
• Completion: 2027-04-01
• First posted: 2025-03-07
• Last updated: 2026-01-30

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study